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Abstract
Introduction CD8+ lymphocytes can suppress HIV replica-
tion without killing the infected cells. This CD8+ cell
noncytotoxic anti-HIV response (CNAR) is associated with
a beneficial clinical course.
Materials and Methods In this longitudinal study of 16
participants in the Options Project at UCSF, we measured
the ability of CD8+ lymphocytes to suppress HIV replica-
tion in CD4+ cells during primary HIV infection, early
antiretroviral therapy, and after treatment.
Results and Discussion CD8+ lymphocytes from subjects
with untreated primary HIV-1 infection strongly suppressed
HIV replication. Initiation of antiretroviral therapy during
primary HIV-1 infection caused a marked decline in this
CNAR. CD8+ cells from these subjects regained anti-HIV
activity when early therapy was discontinued. The timing of
the appearance of CD8+ cell anti-HIV activity directly cor-
related with the emergence of detectable virus levels. Maximal
CNAR activity coincided with a decay in the kinetics of HIV
replication. In addition, peak viral loads during treatment
interruption were lower than pre-treatment virus levels (median
reduction=0.8 logs, p=0.005) and CD4+ T cell counts were
maintained for a 24-week period of follow-up.
Conclusion These results suggest that CNAR plays an
important role in suppressing HIV replication in the setting
of antiretroviral treatment interruption in HIV-infected
individuals.
Keywords Primary HIV-1 infection . antiretroviral therapy .
treatment interruption . host immunity
Introduction
A major objective of the Options Project at the University
of California San Francisco (UCSF) has been to evaluate
the potential benefits of initiating antiretroviral therapy
(ART) very early in the course of HIV infection [1].
During the past 10 years, 544 subjects undergoing primary
HIV-1 infection were enrolled in the Options Project.
Close observation of these participants, including 314
subjects who elected to initiate ART immediately or
within 1 year of enrollment, has allowed for the clinical,
virologic, and immunologic characterization of early
treatment [1]. Notable features of early ART include the
durable suppression of HIV replication, the maintenance
of CD4+ cell numbers [2], preservation of B- and T-cell
repertoire diversity [3, 4], and the waning of anti-HIV
immune responses [5, 6].
The periodic application of ART continues to be
evaluated for its potential clinical benefits. It has been
speculated that structured treatment interruption (STI) may
have an autovaccination-like effect and thereby enhance
anti-HIV immune responses [7]. STI has been most
carefully studied in the subjects with chronic and advanced
HIV infection and several reports have noted that, in this
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context, some individuals rapidly progress to disease [8–
11]. Thus, STI protocols appear to be contraindicated for
subjects who initiate ART during the chronic and advanced
stages of HIV infection. However, STI in subjects treated
during early HIV infection (STIe) may have a more positive
outcome [12–15].
Numerous studies have described the anti-HIV functions
of CD8+ lymphocytes and their importance in HIV
infection [16–21]. Distinct from their classical cytotoxic
function, CD8+ cells can suppress HIV replication through
noncytotoxic mechanisms [17, 18, 21–24]. The CD8+ cell
noncytotoxic anti-HIV response (CNAR) is particularly
relevant because of its direct correlation with a healthy
clinical state [25–29]. Asymptomatic long-term survivors of
HIV infection have strong CNAR activity, whereas this
response is lost with progression to disease [26–32].
Additional features of CNAR include (1) its effectiveness
on divergent strains and subtypes of HIV [22, 28, 33], (2)
its specific effect of blocking LTR-driven transcription [34–
36], and (3) its association with the secretion of the CD8+
cell antiviral factor (CAF) [18, 36–38]. Therapeutic
approaches that enhance CNAR/CAF might be beneficial
to HIV-infected individuals.
The objective of this study was to evaluate the CD8+
cell noncytotoxic anti-HIV response in subjects that
discontinued antiretroviral therapy that was initiated
during primary HIV-1 infection. The results from this
study provide insights into the relationships between pre-
existing CD8+ cell antiviral activity and emerging HIV
replication.
Materials and Methods
Human Subjects The 16 subjects in this study (Table I)
were enrolled in the Options Project at UCSF upon a
diagnosis of primary HIV-1 infection [39, 40]. These
subjects initiated standard antiretroviral treatment (ART;
e.g., 300 mg zidovudine, 150 mg lamivudine, and 1250 mg
nelfinavir twice daily or a similar regimen) within 6 months
of their estimated infection dates. After maintaining HIV
RNA plasma viral loads (VL) below 50 copies/ml for at
least 16 weeks, these subjects elected to discontinue ART
and participate in this study of structured treatment
interruption approved by the UCSF Committee on Human
Subjects.
HIV-1 viral load measurements and clinical blood cell
counts Plasma viral loads (HIV-1 RNA copies /ml) were
measured using the branched-chain DNA test (Seimens
Diagnostics, Emeryville, CA) [41]. Complete differential
blood cell counts for red cell number, hemoglobin, total
leukocytes, granulocytes, lymphocytes, monocytes, plate-
lets, and T cell subsets were performed by Quest Labora-
tories (San Jose, CA).
Cell specimens Whole-blood samples were collected in
evacuated blood tubes (Vacutainer, Becton Dickinson, San
Jose, CA) containing acid–citrate–dextrose at regular inter-
vals during the course of the study. Peripheral blood
mononuclear cells (PBMC) were isolated by density gradient
separation, cryopreserved in fetal bovine serum (FBS)

















S01 1962 1 2/98 5/98 925 1125 2.7 3/03 574 560
S02 1961 2 6/98 9/98 704 448 4.8 9/02 1484 700
S03 1964 2 7/98 10/98 375 780 4.4 1/03 850 493
S04 1960 2 9/98 11/98 667 1242 5.9 8/02 715 403
S05 1962 1 2/99 5/99 432 864 4.0 12/02 864 960
S06 1959 1 6/99 9/99 425 748 4.9 1/03 1848 336
S07 1964 2 1/00 7/00 638 1386 4.9 4/05 1075 677
S08 1967 2 6/00 7/00 720 780 4.8 4/05 1121 361
S09 1973 2 7/00 9/00 720 920 4.1 9/02 1920 1360
S10 1961 2 8/00 11/00 725 1250 4.6 11/03 1989 1014
S11 1941 2 8/00 10/00 385 396 5.6 11/02 1080 1008
S12 1970 2 4/01 5/01 780 740 5.3 2/03 1550 868
S13 1967 2 6/01 7/01 1012 770 5.7 10/02 1050 546
S14 1970 2 7/01 10/01 432 954 5.7 3/03 1312 1088
S15 1947 2 12/02 2/03 520 1220 5.0 12/05 860 677
S16 1965 2 2/04 4/04 559 3635 5.7 4/05 774 688
a Race: 1 Latino/Hispanic, 2 White/non-Hispanic
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containing 10% DMSO, and stored in ultra-low-temperature
freezers before use.
CD8+ cell antiviral responses CD8+ cell noncytotoxic
anti-HIV activity was assessed as the ability of CD8+ cells
to suppress HIV replication in primary CD4+ cells as
previously described [21, 29]. All cell specimens from each
subject were thawed and processed simultaneously. We
have previously determined that cryopreservation does not
substantially affect CNAR activity [27]. Briefly, CD4+ and
CD8+ cells were serially isolated by positive selection
using immunomagnetic beads (Miltenyi, Oslo, NO) from
the PBMC of the study subjects and healthy uninfected
blood donors. The CD4+ cells were stimulated with PHA
(3 μg/ml, Sigma) for 3 days and then acutely infected with
the β-chemokine-resistant strain HIV-1SF33 (10
4 TCID50
per 107 cells per ml) [25, 29, 42, 43]. Unstimulated CD8+
cells were cocultured with autologous HIV-infected CD4+
cells at ratios of 0.25:1, 0.5:1, 1:1 in a total volume of
200 μl of complete medium (RPMI medium 1640, 10%
FBS, antibiotics, 100 U/ml rIL-2, and 2 mM L-glutamine).
When sufficient numbers of cells were available, CD8+
cells were also cocultured with acutely infected heterolo-
gous CD4+ cells. Duplicate wells were established in
96-well flat-bottom plates. HIV replication levels were
determined by measuring the reverse transcriptase (RT)
activity present in the cell culture supernatants as described
previously [44]. CNAR activity (percent suppression) was
evaluated as a ratio of the RT activity in wells containing
CD4+ cells cultured in the presence and absence of CD8+
cells.
Statistical Analysis Data were compiled in an Access
database (Microsoft, Seattle, WA). Descriptive values and
statistical comparisons were computed using S-PLUS 6.1
(Insightful, Seattle, WA). Graphs were prepared using
SigmaPlot 8 (Systat, San Jose, CA).
Results
Demographic and clinical characteristics of the subjects
electing to discontinue early therapy All 16 participants in
this study (Table I) were men who reported having sex with
men as their primary risk of HIV infection. The median age
at the time of infection was 37 years (range=27–59 years).
Among these men, ART was initiated at a median of
79 days (range=30–180 days) following the estimated date
of infection. Due to decreased CD4+ T cell counts and/or
elevated CD8+ T cell levels, 13 of the 16 subjects exhibited
an inverted T cell ratio at the time ART was initiated. At the
time therapy was discontinued, each subject had an
undetectable plasma virus level and only one subject
exhibited an inverted T cell ratio. The median duration of
ART prior to STIe was 3.4 years (range=0.9–4.8 years).
Changes in viral load and T cell counts during STIe To
evaluate the effects of discontinuing early treatment on
clinical parameters, longitudinal measurements of HIV viral
load, CD4+ T cell, and CD8+ T cell counts were analyzed
(Fig. 1). Following cessation of treatment, the median
elapsed time at which the HIV viral load exceeded 500
RNA copies/ml was 4 weeks (interquartile range, IQR=3–
5 weeks). Viral loads were generally observed to reach a
peak level 4–8 weeks post-treatment (Fig. 1a). In compar-
ison to pre-treatment virus levels, maximum viral loads in
the first 8 weeks of STIe were lower in 15 of 16 subjects
(Fig. 1b, median reduction=0.8 logs, p=0.005, paired
t-test). The one exception was a subject (S01) who initiated
therapy without ever having a detectable viral load. Seven
of the nine subjects who discontinued early ART for at least
24 weeks experienced modest CD4+ cell declines during
the first 8 weeks of STIe (Fig. 1c, mean decline=27%,
p=0.013, paired t-test). However, this loss of CD4+ cells
appeared to be transient, as only four of the nine subjects
exhibited lower than treatment levels of CD4+ cells at week
24 of STIe. While their CD4+ T cell levels remained
relatively stable over the 24-week STIe interval, the study
subjects exhibited an expansion of CD8+ T cells (Fig. 1d)
during this period. Significantly elevated CD8+ cell counts
became apparent at week 16 (paired t-test, p=0.011) and
persisted at week 24 (p=0.016) of STIe.
Ten of the 16 subjects in this study resumed antiretro-
viral therapy following STIe. In each case, sub-detection
levels of virus (<50 HIV RNA copies/ml) were reached and
maintained (data not shown). No occurrences of drug-
resistant virus replication were noted during the follow-up
period.
Longitudinal measurements of CD8+ cell anti-HIVactivity The
ability of bulk unstimulated CD8+ cells to suppress HIV
replication in acutely infected primary CD4+ cells was
measured among 16 subjects at multiple time points during
the course of primary HIV-1 infection, early antiretroviral
therapy, and upon cessation of therapy (Fig. 2). Although
the study was designed to focus on the first 24 weeks of
treatment interruption, we were able to measure CD8+ cell
anti-HIV activity for longer periods of time following
treatment (years in some cases) among several of the study
subjects. The expected cytopathic effects (CPE e.g., cell
ballooning, syncytia, and cell death) of the CXCR4-tropic
HIV-1SF33 strain used in our assays were visually apparent
in cultures lacking CD8+ cell antiviral activity. In cultures
showing no CPE, HIV quickly replicated and CPE became
evident upon removal of the CD8+ cells. This observation
demonstrated that HIV-infected cells persist in the presence
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of CNAR activity as reported [17, 35]. This CD8+-cell-
mediated suppression of HIV replication was also observed
in cultures containing heterologous CD4+ cells (Fig. 2) [45].
Together, these observations support the presence of non-
cytotoxic and β-chemokine independent CD8+ cell antiviral
activity in the setting of early treatment interruption.
Effect of early treatment and its discontinuation on CD8+
cell anti-HIV activity In evaluating the effect of antiretro-
viral therapy on the CD8+ cell noncytotoxic anti-HIV
response, CNAR activity was measured prior to treatment
and during the course of ART (Fig. 3a). The availability of
pre-treatment cell specimens allowed for assessments of 13
of the 16 study subjects. During the course of treatment,
CD8+ cells from each of these subjects exhibited a
substantial decrease in anti-HIV activity, with the exception
of one subject (S04) whose CD8+ cells exhibited no pre-
treatment anti-HIV activity. Noteworthy is that this subject
displayed the highest viral load at the time of treatment
initiation (see Table I). None of the 16 subjects studied
exhibited appreciable CNAR activity at the time treatment
was discontinued (week 0, Fig. 3b). Our data suggest that
the CD8+ cell anti-HIV response is diminished within weeks
to months upon treatment, although the availability of
specimens proximal to treatment initiation limited our ability
to precisely determine the rate of loss of this response.
To determine the effect of discontinuing early antire-
troviral therapy, for each of the 16 subjects studied, CNAR
activity was measured during ART and treatment interrup-
tion. One or more measurements of CNAR activity were
performed on CD8+ cells from 15 of the 16 subjects during
the first 8 weeks of treatment interruption (Fig. 3b). Each
subject exhibited a dramatic increase in CD8+ cell anti-HIV
activity during this STIe period. Nonlinear regression
analyses indicated that peak levels of CD8+ cell anti-HIV
activity were reached approximately 4 weeks post ART.
The strength of CNAR activity was statistically assessed by
evaluating the percent suppression at graduated cell culture
input ratios (e.g., 1:1, 1:2, or 1:4 ratios of CD8+ cells to
CD4+ cells) and by summing the percent suppression
values across cell culture input ratios (e.g., 1:1+1:2 values).
These approaches did not reveal any appreciable differ-
ences in the strength of CD8+ cell antiviral activity between
study subjects during STIe (data not shown).
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Fig. 1 Changes in viral load
and T cell counts during STIe.
a The kinetics of HIV replica-
tion upon discontinuation of
early ART are shown for the 16
study subjects. Nonlinear re-
gression analyses were per-
formed using a four-parameter
sigmoidal function (dotted line)
and a three-period mixed model
(solid line). b Comparisons of
viral loads at the time ART was
initiated (Txi), discontinued
(ART), and at the peak virus
level during the first 8 weeks of
STIe (STIe). Changes in c CD4+
T cell and d CD8+ T cell counts
are shown for subjects during
STIe. In each plot, each subject
is denoted by a distinct symbol
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Association between viral load and CD8+ cell noncytotoxic
anti-HIV activity Having separately observed reduced
virus levels (Fig. 1b) and strong CD8+ cell HIV-
suppressing activity (Fig. 3b) during STIe, we formally
assessed the relationship between viral load and CNAR.
These variables were stratified by time and then coplotted
(Fig. 3c). A direct correlation between viral load and
CD8+ cell anti-HIV activity was evident. Although varia-
tions in viral loads were observed between subjects during
STIe (Fig. 1a), circulating virus levels increased in all 16
participants during STIe and exhibited a typical kinetics
pattern with peak levels occurring approximately 4 weeks
post ART. Analyses of CNAR activity revealed that very
strong responses had returned by week 4 of STIe in most
subjects (Fig. 3b). Thus, the timing of the return of
maximal CD8+ cell anti-HIV activity (weeks 4–8) coin-
cided with the timing of the decay in the HIV replication
rate (Fig. 3).
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(a) (b) (c) 
Fig. 3 Effects of early antiretroviral therapy and its discontinuation
on CD8+ cell anti-HIV activity. a Shown is the ability of CD8+ cells
from 13 subjects to suppress HIV replication (1:1 CD8+ cell to acutely
infected autologous CD4+ cell culture input ratios) during untreated
primary HIV-1 infection (week 0) and following the initiation of early
antiretroviral therapy. b Shown are longitudinal changes in CNAR
activity during STIe. The dark solid line reveals results of a nonlinear
regression analysis using a four-parameter sigmoidal function. For
panels a and b, CD8+ cells from individual subjects are distinguished
by unique symbols. c Co-plotted are viral loads and CD8+ cell anti-
HIV activity levels at weeks 0 (triangles), 4 (squares), and 8–24
(circles)
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Fig. 2 Longitudinal measure-
ments of CD8+ cell noncyto-
toxic anti-HIV activity. Shown
are representative measurements
of CNAR activity (left y-axis) in
cocultures containing 1:1 input
ratios of CD8+ cells and autol-
ogous (green circles) or heterol-
ogous (purple squares) acutely
infected CD4+ cells. Viral load
values (red diamonds) are indi-
cated on the right y-axis. For
each of the four subjects shown,
ART periods are shaded on the
x-axis
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Discussion
We hypothesized that the early application of antiretroviral
therapy could reduce HIV levels and preserve immune
functions, thereby promoting the CD8+ cell noncytotoxic
anti-HIV response (CNAR) upon treatment interruption. In
this longitudinal study of 16 subjects (Table I), we
measured the ability of CD8+ lymphocytes to suppress
HIV replication at time points during acute and primary
HIV-1 infection, early treatment, and upon discontinuation
of ART. CNAR activity, measured in more than 200 clinical
blood specimens, was evaluated with respect to HIV viral
load and CD4+ T cell count.
In this study, we observed two positive clinical outcomes
of STIe (Fig. 1). First, peak plasma HIV RNA levels,
occurring at 4–8 weeks of treatment interruption (Fig. 1a),
were lower than those observed during untreated primary
HIV-1 infection (Fig. 1b). The observed peak viral loads
during STIe were likely much lower than the theoretical
peak viral loads occurring during the initial weeks of
infection and prior to study enrollment [39]. Second, during
24 weeks of STIe, circulating CD4+ T cell counts remained
relatively stable (Fig. 1c), whereas CD8+ T cells levels
substantially increased (Fig. 1d). These findings agree with
observations in a recent report [15] and implicate a role for
a beneficial immune response(s) during STIe. Our longitu-
dinal analyses of CNAR activity demonstrated that this
response is associated with the observed positive clinical
outcomes.
The effects of early antiretroviral therapy and its
discontinuation on CNAR activity were remarkably consis-
tent (Fig. 2). Upon initiation of early ART (Fig. 3a), the
CD8+ cell anti-HIV activity, commonly found in subjects
with untreated acute and primary infection, decreased. In a
previous study of mitogen-stimulated CD8+ cells, we
observed that CNAR activity, in primary HIV infection
subjects receiving early antiretroviral therapy, declined in
association with reduced viremia [5]. A similar reduction in
CNAR activity has been reported to occur in persons
starting ART during chronic HIV-1 infection [46]. In the
present study using unstimulated CD8+ cells, the effect of
ART appeared to be more substantial and universal. The
observed differences in the sizes of the effects between
these studies suggest that unstimulated CD8+ cells can
provide a more sensitive measurement of CNAR activity.
Another consistently observed pattern was that CNAR
activity quickly returned during STIe (Fig. 3b). All 16
subjects studied experienced a rebound in CD8+ cell anti-
HIV activity during STIe. Importantly, this antiviral re-
sponse returned at approximately week 4 of STIe and
coincided with a tapering of virus replication levels in the
blood (week 4, Fig. 1a). Although many of the subjects
resumed antiretroviral therapy before reaching a clear viral
load set point during STIe, we observed that the peak viral
loads during STIe, occurring 4–8 weeks post-treatment,
were lower than the viral loads at the time treatment was
initiated (Fig. 1b). The subjects who resumed antiretroviral
therapy early in the course of STIe had been randomized to
a group having a very low limit (1,000 HIV RNA copies/
ml) on the allowable plasma viral load. Thus, the virologic
and immunologic responses of those subjects were not
necessarily different from the other participants.
Because of the limited availability of specimens at
crucial time points, we were unable to directly establish
(1) whether or not CNAR activity was elevated during STIe
in comparison to pre-treatment levels and (2) the precise
relationship between virus replication levels and CNAR
activity during the first weeks of STIe. However, the return
of maximal CNAR activity was found to be temporally
correlated with decayed virus replication kinetics during
STIe (Fig. 3c), suggesting that this response plays a
beneficial immunologic role in this setting. We speculate
that immune-based therapies that can preserve CNAR
activity during early ART, such as the use of IL-2 [47] or
IL-15 [48] treatment, may result in an additional reduction
in viral load during STIe.
In summary, we report an association between strong
CD8+ cell noncytotoxic anti-HIV activity and reduced virus
replication levels following the discontinuation of early
antiretroviral therapy. Additional studies are needed to
establish optimal treatment interruption strategies for
enhancing CD8+ cell immune responses that can further
reduce HIV replication levels. At the same time, the
potential complementary contributions of other immune
responses need to be considered.
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